Overview
Quantinuum Inc., a quantum computing company backed by Honeywell, has submitted a registration statement to the U.S. Securities and Exchange Commission seeking to list Class A common stock on the Nasdaq Global Market under the symbol "QNT." The Broomfield, Colorado-headquartered company disclosed the filing on Thursday and provided financial and structural details in the registration statement.
Offering details and underwriters
The company said it plans to offer shares with an anticipated price range between unspecified amounts, and that the number of shares to be offered has not yet been determined. Joint lead active book-running managers on the offering are J.P. Morgan and Morgan Stanley. Jefferies and Evercore ISI are listed as active book-running managers. Quantinuum has reserved up to 5% of the shares for sale to current or former directors, officers, employees, business associates and related persons at the initial public offering price.
Financial performance and cash position
Quantinuum reported net revenue of $5.2 million and a net loss of $136.6 million for the three months ended March 31, 2026. By comparison, for the three months ended March 31, 2025, it reported net revenue of $19.1 million and a net loss of $30.5 million. For the full year ended December 31, 2025, the company recorded net revenue of $30.9 million and a net loss of $192.6 million. The company reported cash and cash equivalents of $677.0 million as of March 31, 2026.
Use of proceeds and corporate structure post-offering
The registration statement states that Quantinuum Inc. intends to use net proceeds from the offering to purchase newly issued Common Units from Quantinuum Holdings at a price per unit equal to the public offering price per share, less underwriting discounts and commissions. Quantinuum Holdings, in turn, plans to use those proceeds for general corporate purposes and to pay expenses associated with the offering. The filing also indicates that, upon completion of the offering, Quantinuum Inc. will be a holding company whose sole asset will be equity interests in Quantinuum Holdings.
Company background and operations
Quantinuum was formed in 2021 through the combination of Honeywell Quantum Solutions and Cambridge Quantum. As of March 11, 2026, the company employed approximately 700 people globally, including more than 450 employees holding advanced PhDs or Master’s degrees. The filing notes that the company has invested in excess of $2 billion in research and development over the last decade. For the year ended December 31, 2025, Quantinuum reported bookings of $79.3 million.
Key points
- Quantinuum filed to list Class A common stock on Nasdaq under the ticker QNT and named J.P. Morgan and Morgan Stanley as joint lead active book-runners.
- The company disclosed recent quarterly and annual revenue and loss figures, along with a cash and cash equivalents balance of $677.0 million as of March 31, 2026.
- Post-offering, Quantinuum Inc. would act as a holding company with equity interests in Quantinuum Holdings; proceeds from the offering are slated to be used to buy newly issued Common Units from the Holdings entity.
Risks and uncertainties
- Quantinuum reported significant net losses in recent periods, including a net loss of $136.6 million for Q1 2026 and $192.6 million for the full year 2025.
- The offering’s price range and number of shares remain unspecified in the registration statement, introducing uncertainty about potential capital raised and dilution.
- Following the offering, Quantinuum Inc. will hold only equity interests in Quantinuum Holdings, making the company dependent on the Holdings entity and its use of offering proceeds for corporate purposes and expense payments.
Conclusion
The SEC registration filing provides a snapshot of Quantinuum’s financial position, corporate structure and intended use of proceeds ahead of a Nasdaq listing under the symbol QNT. The filing discloses material financial metrics and staffing information while leaving key offering terms, including price range and share count, unspecified at this stage.